04 December, 2013. Link here. Leading veterinary biologic drug developer Nexvet Biopharma (Nexvet) today announced promising clinical data in support of its novel compound NV-01 for treating acute and chronic pain in dogs.
Chairman’s Address to 2013 Annual General Meeting here. AGM outcome of resolutions here.
ASX announcement here. Bioxyne Limited (ASX code: BXN or the Company) advises that subsequent to the execution of a non-binding Heads of Agreement (HOA) to sell its HI-164 oral Vaccine project together with all of its Intellectual properties (IP) to Mariposa Health Limited (MHL), Dr. Phillip Comans has stepped down as Chief executive Officer of the […]
Please find the ASX announcement here. Bioxyne divests its COPD related HI-164OV research program for up to $1.56 million.
..Two largest shareholders to vote against remuneration report 20 November 2013: Leading Australian life sciences investment group BioScience Managers today confirmed it will vote against the remuneration report of spray-on skin company Avita Medical Limited (ASX:AVH) at the company’s AGM on Friday 22 November. With the company’s largest shareholder Australian Ethical also set to vote against […]
Biota Initiates Additional Clinical Trials of Laninamivir Octanoate Link here. ATLANTA, Nov. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza. One of the Phase 1 clinical trials is a […]
Financial report 2013 link here.
Link here. Date of Meeting: 22 November 2013 Time of Meeting: 2pm WST Place of meeting: Function Room, QV1, 250 St Georges Terrace, Perth, WA 6000
Link to the investor presentation here.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: